They focus on the development of novel antibody therapeutics. Their clinical pipeline includes targeted therapeutics in immunology and oncology.
| Contact Details | 9F, Bldg. A, Korea Bio-Park, 700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do |
|---|
Find out more companies
Related products
-
VentureAprogen
Their main modalities include SDR-Grafting, Recombinant Protein Fusion, CHIMPS Bispecific Antibodies, SHOCAP Bispecific Antibodies, and Bitargeting Receptor-Antibody Hybrid
-
-
-
-
Venture
K-Cell Co., Ltd.